CD8A and neoplasm: In the whole cohort, MVA demonstrated low CD8 to be predictive of disease recurrence (HR 1.6, CI 1.1–2.3, p = 0.015) in a final model adjusted for lymph node status, endocrine therapy, tumour size and margin status (Table S8).